Crystal Bio Solutions logo

Sep 18, 2025

An Immunogenicity Analysis Strategy to Reduce Interference from Soluble Target Proteins

Case study: a target-specific blocking antibody removed false-positive ADA signals caused by soluble drug target in four of five serum samples.

ADA Assay Strategy to Reduce Soluble Target Interference\

Summary: In an affinity capture elution (ACE) ADA assay on the MSD platform, adding a target-specific blocking antibody after acid dissociation removed false-positive signals caused by soluble target protein in four of five serum samples.

Objective

Therapeutic proteins carry a higher immunogenicity risk than small molecules, and ADA can reduce exposure and efficacy or cause adverse events. Soluble drug target in the sample can also bridge the labeled drug and produce false-positive ADA results. This study developed a strategy to remove that interference.

Challenge

Soluble target present in study samples can generate false-positive ADA results, which affects immunogenicity reporting and the interpretation of PD, efficacy and safety.

Approach

In an ACE ADA assay on the MSD platform, acid-dissociated samples were treated with a specific antibody that blocks the soluble target, preventing it from being captured and eluted with the ADA.

Affinity capture elution ADA assay with and without a blocking antibody against the soluble target
Figure 1. Affinity capture elution (ACE) ADA assay on the MSD platform. Top: the soluble target is carried through and can cause false-positive signals. Bottom: a blocking antibody binds the soluble target and prevents its capture.

Results

Drug tolerance
PC (ng/mL)100 µg/mL drug300 µg/mL drug500 µg/mL drug
900PositivePositivePositive
300PositivePositivePositive
100PositiveNegativeNegative
30NegativeNegativeNegative
0NegativeNegativeNegative

The assay detected 100 ng/mL PC in the presence of 100 µg/mL drug, and 300 ng/mL PC in the presence of at least 500 µg/mL drug.

Soluble target interference (spiked target concentration)
Serum sampleBasal level, no blocking antibodyBasal level + blocking antibody+20 µg/mL target + blocking antibody+50 µg/mL target + blocking antibody
Serum 01PositiveNegativeNegativeNegative
Serum 02PositiveNegativeNegativeNegative
Serum 03PositiveNegativeNegativeNegative
Serum 04PositivePositivePositivePositive
Serum 05PositiveNegativeNegativeNegative

Without the blocking antibody, all five sera screened positive. With the blocking antibody, four of five became negative, including after spiking 20 or 50 µg/mL of target, consistent with soluble target interference. Serum 04 remained positive under all conditions.

Sensitivity curves of signal-to-noise ratio versus positive control concentration with and without blocking antibody
Figure 2. Sensitivity curves (signal-to-noise ratio vs. positive control concentration, ng/mL) with and without the blocking antibody.

Conclusions

Treating samples with a target-specific blocking antibody is an effective way to reduce soluble target interference in ADA assays for therapeutic proteins.

Related services: ADA and NAb immunogenicity assays.

Download the case study

Fill in the short form below and we will email you the PDF (1 page, 659 KB).

To discuss a similar study, email cbs_bd@crystalpharmatech.com or call +1 925-558-5040.